These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 28035744)
1. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744 [TBL] [Abstract][Full Text] [Related]
2. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413 [TBL] [Abstract][Full Text] [Related]
3. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326 [TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
5. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382 [TBL] [Abstract][Full Text] [Related]
6. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
7. Molecular Cytogenetics Detect an Unbalanced t(2;13)(q36;q14) and PAX3-FOXO1 Fusion in Rhabdomyosarcoma With Mixed Embryonal/Alveolar Features. La Starza R; Nofrini V; Pierini T; Pierini V; Zin A; Bisogno G; Cerri C; Caniglia M; Sidoni A; Ludwig K; Mecucci C Pediatr Blood Cancer; 2015 Dec; 62(12):2238-41. PubMed ID: 26179572 [TBL] [Abstract][Full Text] [Related]
8. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
9. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Gordon A; McManus A; Anderson J; Fisher C; Abe S; Nojima T; Pritchard-Jones K; Shipley J Cancer Genet Cytogenet; 2003 Jan; 140(1):73-7. PubMed ID: 12550764 [TBL] [Abstract][Full Text] [Related]
10. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Hettmer S; Linardic CM; Kelsey A; Rudzinski ER; Vokuhl C; Selfe J; Ruhen O; Shern JF; Khan J; Kovach AR; Lupo PJ; Gatz SA; Schäfer BW; Volchenboum S; Minard-Colin V; Koscielniak E; Hawkins DS; Bisogno G; Sparber-Sauer M; Venkatramani R; Merks JHM; Shipley J Eur J Cancer; 2022 Sep; 172():367-386. PubMed ID: 35839732 [TBL] [Abstract][Full Text] [Related]
11. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies. Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109 [TBL] [Abstract][Full Text] [Related]
13. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome? Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K; Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833 [TBL] [Abstract][Full Text] [Related]
14. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group. Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH; Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526 [TBL] [Abstract][Full Text] [Related]
15. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma. Thway K; Wang J; Wren D; Dainton M; Gonzalez D; Swansbury J; Fisher C Virchows Arch; 2015 Aug; 467(2):217-24. PubMed ID: 25912319 [TBL] [Abstract][Full Text] [Related]
16. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739 [TBL] [Abstract][Full Text] [Related]
17. Detection of PAX3/PAX7-FKHR fusion transcripts in rhabdomyosarcoma and other small round cell tumors by 1-step reverse transcriptase polymerase chain reaction: a novel tool for diagnosis and differentiation. Yang XL; Zhang SC; Zhang SW; Wang H Ann Diagn Pathol; 2012 Apr; 16(2):107-11. PubMed ID: 22197543 [TBL] [Abstract][Full Text] [Related]
18. Update on molecular findings in rhabdomyosarcoma. El Demellawy D; McGowan-Jordan J; de Nanassy J; Chernetsova E; Nasr A Pathology; 2017 Apr; 49(3):238-246. PubMed ID: 28256213 [TBL] [Abstract][Full Text] [Related]
19. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361 [TBL] [Abstract][Full Text] [Related]
20. Molecular diagnostics in the management of rhabdomyosarcoma. Arnold MA; Barr FG Expert Rev Mol Diagn; 2017 Feb; 17(2):189-194. PubMed ID: 28058850 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]